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Background
Pulmonary hypertension has a high mortality, in part
because of the paucity of selective pulmonary vasodila-
tors. We have demonstrated previously that the phos-
phodiesterase (PDE) 5 inhibitor sildenafil augments
dilatation to atrial natriuretic peptide (ANP) in the pul-
monary, but not systemic, vasculature. This supports the
hypothesis that cGMP-mediated vasodilatation by ANP is
regulated by PDE V specifically in the pulmonary vascular
bed, and that modulation of the natriuretic peptide sys-
tem could be beneficial in the treatment of pulmonary
hypertension.
Materials and methods
Male Sprague Dawley rats were divided into groups, pre-
treated with either ecadotril (neutral endopeptidase
[NEP]inhibitor; prevents natriuretic peptide hydrolysis)
60 mg/kg/day by gavage, sildenafil 30 mg/kg/day in the
drinking water, or a combination of both, and subjected
to 2 weeks of hypoxia (10% oxygen) to induce pulmonary
hypertension. Hypoxic and normoxic controls were also
included. After two weeks, pulmonary, right ventricular
and systemic pressures were determined by fluid filled
catheterisation in anaesthetised animals. Animals were
then euthanised and hearts and lungs excised for further
analysis.
Results
In untreated control rats, 2 weeks of 10% hypoxia pro-
duced markedly elevated mean pulmonary pressures
(28.9 ± 2.2 mmHg) as compared to normoxia controls
(18.44 ± 1.9 mmHg; P < 0.05). Both sildenafil treated
(24.07 ± 0.5 mmHg) and ecadotril treated (25.45 ± 1.4
mmHg) animals showed a statistically significant reduc-
tion in PAP with a further reduction (21.27 ± 1.4 mmHg)
observed in the combined treatment group. Similarly, 2
weeks of hypoxia produced a doubling of the right ven-
tricular systolic pressure (RVSP) in untreated hypoxic rats
(41.2 ± 2.0 mmHg) as compared to normoxia controls
(26.8 ± 6.6 mmHg; P < 0.05). Treatment with sildenafil
(40.2 ± 4.5 mmHg) or ecadotril (41.3 ± 4.5 mmHg) alone
failed to reduce RVSP, but the sildenafil + ecadotril group
showed reduced RVSP (35.3 ± 1.8 mmHg; P < 0.05). Sys-
temic blood pressure was not changed in any of the
groups. In accord with the changes in pulmonary haemo-
dynamics, the right ventricular hypertrophy (right to left
ventricle weight ratio) and vascular remodelling in the
lung (% of muscularised vessels) following hypoxia were
reduced with each of the treatment regimes.
Conclusion
These data suggest that a combination of sildenafil and
ecadotril has a synergistic effect to lower pulmonary arte-
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rial pressure in pulmonary hypertension. However, there
is no effect of this combination on systemic blood pres-
sure, so the presence of NEP blockade appears to increases
the pulmonary selectivity of sildenafil, and this combina-
tion treatment might be of therapeutic benefit in treating
pulmonary hypertension.Page 2 of 2
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